GSK, Google parent forge £540m bioelectronic medicines firm
Tie-up will develop miniaturised, implantable devices that can modify electrical nerve signals
London
GLAXOSMITHKLINE (GSK) and Google parent Alphabet's life sciences unit are creating a new company focused on fighting diseases by targeting electrical signals in the body, jump-starting a novel field of medicine called bioelectronics.The tie-up shows the growing convergence of health care and technology.
Verily Life Sciences - known as Google's life sciences unit until last year - and Britain's biggest drugmaker will together contribute £540 million (S$953.9 million) over seven years to Galvani Bioelectronics, they said on Monday.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Technology
Brokers’ take: DBS cuts Venture Corp price target after Q1 earnings miss
Garmin’s Q1 results beat on strong demand for fitness, auto products
Foxconn’s musical chairs sound like punk rock
US sets up board to advise on safe, secure use of AI
Regulate AI? How US, EU and China are going about It
Meta’s results are best viewed through rose-tinted AI glasses